Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Caprion is proud to offer an expanded range of solutions for clinical and translational research
with the addition of IMMUNECARTA Services to complement its established proteomic biomarker
services business. The pairing of Caprion’s traditional strengths in biomarker and target discovery
with IMMUNECARTA’s immune monitoring expertise, provides a powerful combination of solutions
for all phases of drug and vaccine development.
IMMUNECARTA’s capabilities include analysis of phenotypic and functional profiles of innate and adaptive immune responses in
a GLP/GCLP compliant environment. Our immune monitoring expertise is applied to preclinical drug development and phase I/II
clinical trials across many key therapeutic indications.
ThERApEUTIC AREAS
IMMUNE MONITORING SERVICES
gCellular therapy
gDrug therapy
gCancer immunotherapy
gVaccine development
gInfectious diseases
gAutoimmune disorders
gChronic inflammatory diseases
gImmunosenescence
gFlow cytometry-based assays
gMultiplex beads-based assays
gELISpot assays
gELISA assays
ASSAY TYpESThe IMMUNECARTA team has enabled a number of different assay formats for
assessment of subtle and often complex changes in immune response. Each assay may be customized to address
client and study-specific needs for flexibility and scalability for vaccine trials, immunotherapy trials, or part of an overall
assessment of immunocompetence or immune reconstitution as a result of therapy.
For a comprehensive overview of assays, see chart inside.
CA
P_2
01_2
012
Integrated solutions for the advancement of personalized medicine
For more information contact us at 1-877-776-3443 or [email protected]
ExpERIENCE ThE dIffERENCE
caprion.comIN IMMUNE MONITORING
plaTfORM fIEld Of applICaTION MaIN ThERapEUTIC aREa
CaTEGORIES Of aSSaySBIOlOGICal
COMpaRTMENTMaRkERS
CU
ST
OM
Iza
Bl
E
flO
w C
yT
OM
ET
Ry
Cy
TO
kIN
E B
Ea
d
aR
Ra
y (
CB
a)
El
ISa
/El
ISp
OT
Ch
EM
IlU
MIN
ES
CE
NC
E
MO
lE
CU
la
R
BIO
lO
Gy
dR
UG
dE
VE
lO
pM
EN
T
BIO
Ma
Rk
ER
S
BIO
lO
GIC
S/
BIO
SIM
Ila
RS
IMM
UN
E
MO
NIT
OR
ING
Va
CC
INE
Ep
ITO
pE
M
ap
pIN
G
IMM
UN
OTO
xIC
OlO
Gy
INf
EC
TIO
US
d
ISE
aS
ES
al
lE
RG
y
ON
CO
lO
Gy
Ca
Rd
IOlO
Gy
aU
TO
IMM
UN
ITy
TR
aN
Sp
la
NTa
TIO
N
IMM
UN
E
SE
NE
SC
EN
CE
Ch
RO
NIC
IN
fl
aM
Ma
TIO
N
Cellular enumeration
hematopoietic stem cells Circulating Cd34+ Cd34, Cd45, others 4 • • • • • •
Immune Cells T, B and Innate cellsCd3, Cd4, Cd8, Cd16/56, Cd19, Cd14, Cd11c, Cd45,
Cd123, others4 • • • • • • • • • • • • • •
Cellular PhenotyPing
Cell lineage
T cells
B cells
Nk cells
NkT cells
dendritic cells
Basophils
Monocytes
Cd3, Cd4, Cd8
Cd19, hla-dR
Cd16, Cd56, lin-
Va24, aGalCerCd1d tetramer, Cd3
Cd11c, Cd123, lin-
Cd123, lin-
Cd14
4 • • • • • • • • • • • • • • •
Cell Subset differentiation
T cells
B cells
Nk cells
dendritic cells
Basophils
Monocytes
Cd45Ra/RO, Cd27, CCR7, Cd28, Cd62l
Cd27, Igd/M, Cd20, Cd38, Cd10, Iga/G/E
Cd94/NkG2a, Cd7, kIR2dl/dS
Cd11c, Cd123, BdCa-2/3/4,
fcgRs, IgE, CCR3
Cd16, Cd64, fcgRs
4 • • • • • • • • • • • • • • •
antigenic specificity antigen-specific Cd8+/Cd4+ T cellsantigen-specific, hla-restricted TCR
(using Tetramer/pentamer/dexamer)4 • • • • • • • • • •
activation/Inhibition/
Exhaustion/Immune
Senescence
T, B and Innate cells
hla-dR, Cd38, ICOS, Ox40, 4-1BB, ki67, Cd40,
Cd95, pd-1, Cd57, Cd83, Cd80, Cd86, Cd160,
lag-3, 2B4, CTla-4, Tim-34 • • • • • • • • • • • • • • •
homing Receptors/
Co-receptorsT cells, B and Innate cells
CCR4, CCR5, CCR6, CCR7, CCR9, CxCR3,
a4b7 integrins, others4 • • • • • • • • • • • • •
Transcriptional factors Treg, Th1, Th2, Th17, Tfh foxp3, T-bet, GaTa-3, RORgt, BCl-6 4 • • • • • • • • • • •
FunCtional ProFiling
Intracellular Cytokine/
Chemokine Staining (ICS)
T, B, Nk, NkT, dendritic cells,
Monocytes
Il-2, TNfa, IfNg, Il-4, Il-17, Il-22, Il-10, TGfb,
Il-9, Il-21, Mip1b, others4 • • • • • • • • • • • • • • •
apoptosis/Necrosis T, B and Innate cellsannexin, caspase 3, Cd95, paRp, TUNEl,
live/dead, 7-aad4 • • • • • • • • • • • • • • •
phosphorylation
(phosflow)
T, B and Innate Cells,
Tumor cells
akt, Btk, Elk, EGf-R, lck, laT, zap70, Syk,
MEk1, NfkB, pkC, plC-g1, plC-g2, p38Mapk,
ERkk1/2 Src, STaT1 to STaT-64 • • • • • • • • • • • • •
proliferative capacity
(Immuknow®)Total Cd4 cells aTp • • • • • • • • • •
proliferative response/
cell cyclingT cells and subsets CfSE, ki67, BrdU 4 • • • • • • • • • • • • • • • •
ElISpOT Cd8+/Cd4+ T cells, B cells IfNg and/or Il-2, TNfa, IgG, IgM 4 • • • • • • • • •
Cytotoxicity/degranulationT, Nk, NkT cells and
subsets, BasophilsCd107a, Granzyme, perforin, Cd63, others 4 • • • • • • • • • • • • • • •
Serology & Soluble markerS
antibody TitersSerum, plasma, cell culture superna-
tants
Tetanus, diphtheria, hepatitis B, Cholera toxin B,
CMV, others • • • • • • • • • • •
Cytokines/Chemokines/
adhesion Molecules/Growth factors
Serum, plasma,cell culture superna-
tants
Interleukins, sICaM-1, sICaM-3, sVCaM-1,
spECaM-1, sE-Selectin, sp-Selectin, G-CSf, Il-8,
MCp-1, MIG, MIp-1a, MIp-1b, others4 • • • • • • • • • • • • • • • •
gene exPreSSion & Dna analySiS
mRNa expression
(real-time pCR)Cells, tissue Specific mRNa quantification 4 • • • • • • • • • • • • •
T cell receptor excision circles (TREC) Cells, tissue sjTREC • • • • • • • •
IMMUNECaRTa SERVICES: dEEp ExpERTISE IN IMMUNE RESpONSE MONITORING USING flOw CyTOMETRyIMMUNECaRTa aSSay MaTRIx
I M M U N E C A R T A C A P R I O N I M M U N E M O N I T O R I N G S O L U T I O N S
I M M U N E C A R T A C A P R I O N I M M U N E M O N I T O R I N G S O L U T I O N S
gFlow Cytometry – State-of-the art instrumentation with up to 14 colour multi-parametric technology
gImmune Cell Characterization – Discrimination and enumeration of immune cells and subtypes
according to phenotype, function and frequency
gBroad Assay Portfolio and Expertise – Cell-mediated immunity and epitope mapping.
Signaling pathways. Serology and profiling of soluble markers
gValidated Assays – Off-the-shelf kits or on-demand fully customized and validated assays
gLogistics Support – Coordination of sample procurement and analysis, client training
gSample Collection and Processing Services – Validated protocols with option to direct-ship samples
from clinical sites for centralized processing by IMMUNECARTA Services.
gOnsite or Web-Based Training Options – For multi-center trials and remote clinical sites to ensure
consistent sample processing and preparation across sites
IMMUNE MONITORING CApABILITIES
Integrated solutions for the advancement of personalized medicine
CONSULTING SERVICESgImmunology and Technical Expertise – For assessment of study requirements appropriate to the
immune responses of interest. Scientific intellectual leadership and study management of active programs
gTrial Design – As per client need, for delineation of subtle immunologic events and clinical endpoint measurement
gAssay Selection – Evaluation and recommendations for development, customization, validation and deployment
gData Interpretation – Synthesis, analysis and interpretation of complex datasets to infer biological significance
and convey meaning to the immune response, by expert staff immunologists
QUALITY MANAGEMENT SYSTEMgGood Laboratory Practice – IMMUNECARTA operates in accordance with applicable GLP/GCLP regulations
and guidelines, under which studies are planned, conducted, monitored, reported and archived
gQuality Management System – Ensures validation and standardization of immune assays with
rigorous quality control standards, from sample collection to final data reporting
gSuccessful Quality Audits – Successfully audited by a number of major
pharmaceutical clients and independent auditing firms
For more information contact us at 1-877-776-3443 or [email protected]
1
2
3